Quality measures and benchmarking for warfarin therapy.

J Thromb Thrombolysis

Clinical Pharmacy Research and Applied Pharmacogenomics, Kaiser Permanente Colorado, 16601 East Centretech Parkway, Aurora, CO 80011, USA.

Published: April 2011

AI Article Synopsis

  • The goal of warfarin therapy is to prevent blood clots while minimizing the risk of major bleeding, achieved by maintaining the right therapeutic levels as measured by INR.
  • Effective management of warfarin relies on various components working together, and the quality of care can be assessed through outcomes, processes, and organizational structures.
  • With new oral anticoagulants available, there is a growing need for a structured quality measurement program for warfarin management to ensure its effectiveness compared to these alternatives.

Article Abstract

The ultimate goal of warfarin therapy, to prevent thromboembolism with the lowest possible risk of major bleeding complications, is most likely to be realized when therapeutic anticoagulation as measured by the international normalized ratio (INR) is quickly achieved and maintained in appropriate candidates. Realizing this goal requires optimal functioning of various anticoagulation management system components. The extent to which these components function smoothly together determines the quality of warfarin therapy management. A quality measure is used to ascertain the degree to which a given system is successfully coordinating care to accomplish a particular therapeutic goal. The quality of care can be evaluated at different levels such as outcomes (e.g. INR results, major bleeding, thromboembolism, death), processes (e.g. method used to adjust warfarin doses), and structures (e.g. clinic organization structure, workload statistics). There is great need for a structured program of quality measurement for warfarin therapy management. The arrival of new options for oral anticoagulation medications increases the need for credible information regarding the site-specific quality of warfarin therapy management because the potential advantages over warfarin therapy associated with some of these agents are in part dependent upon the quality of warfarin therapy management.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-011-0570-0DOI Listing

Publication Analysis

Top Keywords

warfarin therapy
28
therapy management
16
quality warfarin
12
warfarin
8
major bleeding
8
quality
7
therapy
7
management
5
quality measures
4
measures benchmarking
4

Similar Publications

Limited available evidence comparing DOACs with warfarin suggests efficacy and safety of DOACs for CVT. We aimed to evaluate whether a specific DOAC is preferred for the treatment of CVT. This retrospective cohort study included adult patients with CVTs between September 2018 and September 2022 treated with a DOAC.

View Article and Find Full Text PDF

Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent.

Am J Case Rep

January 2025

Department of Clinical Diagnostic Laboratories, Hospital Al-Sultan Abdullah, Puncak Alam, Selangor, Malaysia.

BACKGROUND Lupus anticoagulants (LA) can interfere with routine coagulation tests such as the activated partial thromboplastin time (aPTT) and prothrombin time (PT). The international normalized ratio (INR) is derived from PT and is used to monitor warfarin therapy. A positive LA result is one of the laboratory criteria of the 2023 ACR/EULAR antiphospholipid syndrome (APS) classification criteria.

View Article and Find Full Text PDF

Background: Guideline-recommended strategies to interrupt chronic anticoagulation with warfarin or direct oral anticoagulants (DOAC) during the perioperative period of cardiac implantable electronic device (CIED) surgery differ worldwide. There is uncertainty concerning the benefits and harms of interrupted and uninterrupted anticoagulation in patients undergoing CIED surgery.

Objectives: To assess the benefits and harms of interrupted anticoagulation (IAC) with either warfarin or DOAC in the perioperative period of CIED surgery versus uninterrupted anticoagulation (UAC), with or without heparin bridging, during an equivalent time frame, for CIED surgery.

View Article and Find Full Text PDF

Introduction: We investigated the subsequent trends in age and antithrombotic therapy in patients who underwent transurethral resection of bladder tumor (TURBT) and examined the rate of perioperative complications.

Methods: Medical records of patients who underwent TURBT were retrospectively analyzed. We arbitrarily divided the observation years into three periods (I: 2007-2013, II: 2014-2018, and III: 2019-2023) to compare the trends in age and frequency of perioperative complications after TURBT between patients taking and those not taking antithrombotic drugs.

View Article and Find Full Text PDF

Aims: Evidence supporting the prescription of anticoagulant therapy for patients with atrial fibrillation (AF) with advanced chronic kidney disease (CKD) has been limited, and its clinical application in this context remains controversial.

Methods: We identified AF patients with advanced CKD (G4-G5) and a history of stroke who were admitted to the First Affiliated Hospital of Dalian Medical University between January 1, 2011, and June 30, 2023. Patients were classified into warfarin, non-vitamin K antagonist oral anticoagulant (NOAC), antiplatelet therapy, and control (no antithrombotic therapy) groups.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!